Surface Oncology Inc. (NASDAQ:SURF) does about 778.82K shares in volume on a normal day but saw 3960875 shares change hands in Tuesday trading. The company now has a market cap of 244.40M USD and an enterprise value of about $149.34M. Its current market price is $7.14, marking an increase of 9.85% compared to the previous close of $6.50. The 52 week high reached by this stock is $7.66 whilst the lowest price level in 52 weeks is $1.15. The script in recent trading has seen the stock touch a high of $7.25 and a low of $6.35.
Surface Oncology Inc. (SURF) has a 20-day trading average at $6.07 and the current price is -6.79% off the 52-week high compared with 520.87% distance from its 52-week low. The 50-day simple moving average of the closing price is $5.83 and its 200-day simple moving average is $3.53. If we look at the stock’s price movements over the week, volatility stands at 11.58%, which decreases to 10.86% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 64.06 to suggest the stock is neutral.
5 analysts observing the Surface Oncology Inc. (SURF) stock have set the 12-month price targets for the company’s shares at between $9.00 and $12.00. The consensus objective for the share price is $10.75, suggesting that the stock has a potential upside of 33.58% over the period. The median price target is 35.09% away from the current levels at $11.00.
FactSet Research has provided data showing that 5 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 1 advise that it is a overweight. 4 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on August 28, 2020 when Wedbush initiated the stock to “Outperform” and issued a price target of $12. Goldman initiated its price target at $17.
The current price level is 19.19%, 23.51%, and 103.96% away from its SMA20, SMA50, and SMA200 respectively, with the SURF price moving below the 50-day SMA on September 01. Surface Oncology Inc. (SURF) stock is up 27.50% over the week and 37.04% over the past month. Its price is 279.79% year-to-date and 257.00% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.44 above consensus estimates by $0.04. The company’s next earnings report is expected on 11/17/2020, with forecasts estimating quarterly EPS at -$0.4 and -$0.7 for whole year. SURF’s earnings per share are forecast to grow by 64.50% this year and -135.70% over next year.
Its 12-month price target is $11.00. To reach the target analysts have set, the stock logically needs to grow 33.58 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $9.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $12.00.
Outstanding shares total 33.42M with insiders holding 16.76% of the shares and institutional holders owning 62.75% of the company’s common stock. The company has a return on investment of -88.70% and return on equity of -32.90%. Price to book ratio is 2.45 and price to sales ratio is 6.20.
USAA Science & Technology Fund isn’t the only investment manager who changed stakes and is followed by Vanguard Total Stock Market Index, which added 0.15 million shares to end up with 469,526 shares worth $2.45 million.